David Reynolds's PhD research on Huntington's disease models led directly to his current work as CEO and co-founder of LoQus23, a company developing oral treatments for Huntington's and related triplet repeat diseases, while he also serves as Non-Executive Director of AstronauTx. After 18 years at Merck, Lundbeck, and Pfizer—including running Pfizer's Cambridge Neuroscience & Pain site—and later serving as Chief Scientific Officer of Alzheimer's Research UK, he built a career that spans nearly every stage of turning early research into actual medicines, and he still emphasizes building diverse, trust-based teams like the one at LoQus23, which has 66% female representation and a 50% female leadership team.